Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 3
2019 3
2020 4
2021 4
2022 5
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Growth hormone secretagogues modulate inflammation and fibrosis in mdx mouse model of Duchenne muscular dystrophy.
Boccanegra B, Cappellari O, Mantuano P, Trisciuzzi D, Mele A, Tulimiero L, De Bellis M, Cirmi S, Sanarica F, Cerchiara AG, Conte E, Meanti R, Rizzi L, Bresciani E, Denoyelle S, Fehrentz JA, Cruciani G, Nicolotti O, Liantonio A, Torsello A, De Luca A. Boccanegra B, et al. Front Immunol. 2023 Apr 12;14:1119888. doi: 10.3389/fimmu.2023.1119888. eCollection 2023. Front Immunol. 2023. PMID: 37122711 Free PMC article.
Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care.
Morieri ML, Candido R, Frontoni S, Disoteo O, Solini A, Fadini GP; PIONEERING EXPERIENCE study group. Morieri ML, et al. Diabetes Ther. 2023 Dec;14(12):2159-2172. doi: 10.1007/s13300-023-01490-6. Epub 2023 Oct 18. Diabetes Ther. 2023. PMID: 37848758 Free PMC article.
Importantly, oral semaglutide was started in subjects with various disease durations and background therapies. Notably, its initiation was accompanied by de-prescription of sulfonylureas, pioglitazone, DPP-4 inhibitors, and insulin. ...
Importantly, oral semaglutide was started in subjects with various disease durations and background therapies. Notably, its initiation was a …
Targeting the Gut: A Systematic Review of Specific Drug Nanocarriers.
Garbati P, Picco C, Magrassi R, Signorello P, Cacopardo L, Dalla Serra M, Faticato MG, De Luca M, Balestra F, Scavo MP, Viti F. Garbati P, et al. Pharmaceutics. 2024 Mar 21;16(3):431. doi: 10.3390/pharmaceutics16030431. Pharmaceutics. 2024. PMID: 38543324 Free PMC article. Review.
Noninvasive Ventilation in a Pediatric Trauma Center: A Cohort Study.
Piastra M, De Bellis A, Morena TC, De Luca D, Pezza L, Pizza A, Genovese O, Mancino A, Picconi E, Conti G. Piastra M, et al. J Intensive Care Med. 2022 Feb;37(2):177-184. doi: 10.1177/0885066620983744. Epub 2021 Jan 19. J Intensive Care Med. 2022. PMID: 33461370
Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality.
Sanese P, Fasano C, Buscemi G, Bottino C, Corbetta S, Fabini E, Silvestri V, Valentini V, Disciglio V, Forte G, Lepore Signorile M, De Marco K, Bertora S, Grossi V, Guven U, Porta N, Di Maio V, Manoni E, Giannelli G, Bartolini M, Del Rio A, Caretti G, Ottini L, Simone C. Sanese P, et al. iScience. 2020 Oct 7;23(10):101604. doi: 10.1016/j.isci.2020.101604. eCollection 2020 Oct 23. iScience. 2020. PMID: 33205017 Free PMC article.
22 results